Table 1 Efficacy results
| Â | Â | Number (%) of patients with at least 50% pain relief | Â | Â | Â | |
|---|---|---|---|---|---|---|
Drug and dose | Number of trials | Active | Placebo | Relative benefit (95% CI) | NNT (95% CI) | Route |
Valdecoxib 20 mg | 2 | 69/101 (68) | 8/103 (8) | 8.8 (4.5 to 17.3) | 1.7 (1.4 to 2.0) | Oral |
Valdecoxib 40 mg | 4 | 204/279 (73) | 19/194 (10) | 7.3 (4.8 to 11.2) | 1.6 (1.4 to 1.8) | Oral |
Parecoxib 20 mg | 4 | 85/170 (50) | 29/176 (16) | 3.1 (2.2 to 4.5) | 3.0 (2.3 to 4.1) | Intravenous |
Parecoxib 40 mg | 4 | 109/173 (63) | 29/176 (16) | 3.8 (2.7 to 5.5) | 2.2 (1.8 to 2.7) | Intravenous |
Parecoxib 20 mg | 1 | 32/51 (63) | 2/51 (4) | 16 (4.1 to 63.3) | 1.7 (1.4 to 2.3) | Intramuscular |
Parecoxib 40 mg | 1 | 39/50 (78) | 2/51 (4) | 19.9 (5.1 to 78) | 1.4 (1.2 to 1.6) | Intramuscular |